Taiwan · Delayed Price · Currency is TWD Obigen Pharma Statistics
Total Valuation
Obigen Pharma has a market cap or net worth of TWD 4.03 billion. The enterprise value is 3.60 billion.
| Market Cap | 4.03B |
| Enterprise Value | 3.60B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Obigen Pharma has 106.92 million shares outstanding. The number of shares has increased by 0.75% in one year.
| Current Share Class | 107.23M |
| Shares Outstanding | 106.92M |
| Shares Change (YoY) | +0.75% |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 7.49% |
| Float | 48.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.44 |
| P/TBV Ratio | 7.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.14, with a Debt / Equity ratio of 0.05.
| Current Ratio | 18.14 |
| Quick Ratio | 16.26 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.17 |
| Interest Coverage | -302.55 |
Financial Efficiency
Return on equity (ROE) is -30.51% and return on invested capital (ROIC) is -18.55%.
| Return on Equity (ROE) | -30.51% |
| Return on Assets (ROA) | -18.36% |
| Return on Invested Capital (ROIC) | -18.55% |
| Return on Capital Employed (ROCE) | -34.88% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 36.56 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.62 |
| Average Volume (20 Days) | 111,469 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -424.78M |
| Pretax Income | -414.33M |
| Net Income | -414.33M |
| EBITDA | -325.91M |
| EBIT | -424.78M |
| Earnings Per Share (EPS) | -3.88 |
Balance Sheet
The company has 326.80 million in cash and 58.37 million in debt, with a net cash position of 268.43 million or 2.51 per share.
| Cash & Cash Equivalents | 326.80M |
| Total Debt | 58.37M |
| Net Cash | 268.43M |
| Net Cash Per Share | 2.51 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 10.93 |
| Working Capital | 437.39M |
Cash Flow
In the last 12 months, operating cash flow was -327.26 million and capital expenditures -8.58 million, giving a free cash flow of -335.84 million.
| Operating Cash Flow | -327.26M |
| Capital Expenditures | -8.58M |
| Depreciation & Amortization | 98.86M |
| Net Borrowing | -16.68M |
| Free Cash Flow | -335.84M |
| FCF Per Share | -3.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Obigen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.75% |
| Shareholder Yield | -0.75% |
| Earnings Yield | -10.28% |
| FCF Yield | -8.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |